| __timestamp | MorphoSys AG | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 55962693 | 7459000 |
| Thursday, January 1, 2015 | 78655788 | 11831000 |
| Friday, January 1, 2016 | 95723069 | 25705000 |
| Sunday, January 1, 2017 | 116808575 | 46181000 |
| Monday, January 1, 2018 | 106397017 | 59497000 |
| Tuesday, January 1, 2019 | 108431600 | 65003000 |
| Wednesday, January 1, 2020 | 141426832 | 74506000 |
| Friday, January 1, 2021 | 225200000 | 126006000 |
| Saturday, January 1, 2022 | 297812160 | 126215000 |
| Sunday, January 1, 2023 | 283614139 | 120161000 |
Data in motion
In the competitive world of biotechnology, innovation is the lifeblood of success. MorphoSys AG and Protagonist Therapeutics, Inc. are two companies that exemplify this drive. Over the past decade, MorphoSys AG has consistently outpaced Protagonist Therapeutics in research and development (R&D) spending, with an average annual investment nearly double that of its counterpart. In 2022, MorphoSys AG allocated approximately 136% more to R&D than Protagonist Therapeutics, highlighting its commitment to pioneering advancements. This trend has been evident since 2014, with MorphoSys AG's R&D expenses growing by over 400% by 2023. Meanwhile, Protagonist Therapeutics has shown a steady increase, with a notable 150% rise in R&D spending over the same period. As these companies continue to innovate, their investments in R&D will likely shape the future of biotechnology.
Research and Development: Comparing Key Metrics for Pfizer Inc. and MorphoSys AG
Research and Development: Comparing Key Metrics for argenx SE and Protagonist Therapeutics, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Bio-Techne Corporation and Protagonist Therapeutics, Inc.
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Jazz Pharmaceuticals plc and MorphoSys AG
Halozyme Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Pharming Group N.V. and MorphoSys AG
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Perrigo Company plc vs MorphoSys AG
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE